JP2003530343A - アルドステロンシンターゼインヒビター単体またはａｔ１−レセプターアンタゴニストとの組み合わせの新規医薬使用 - Google Patents

アルドステロンシンターゼインヒビター単体またはａｔ１−レセプターアンタゴニストとの組み合わせの新規医薬使用

Info

Publication number: JP2003530343A
Authority: JP; Japan
Prior art keywords: hypertension; renal failure; combination; receptor antagonist; pharmaceutically acceptable
Prior art date: 2000-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2001574092A

Other languages

English (en)

Japanese (ja)

Inventor

ロナルド・エドワード・スティール

Original Assignee

ノバルティスアクチエンゲゼルシャフト

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2001-04-10

Publication date

2003-10-14

2001-04-10 Application filed by ノバルティスアクチエンゲゼルシャフト filed Critical ノバルティスアクチエンゲゼルシャフト

2003-10-14 Publication of JP2003530343A publication Critical patent/JP2003530343A/ja

Status Pending legal-status Critical Current

Links

239000002333 angiotensin II receptor antagonist Substances 0.000 title claims abstract description 25
229940123338 Aldosterone synthase inhibitor Drugs 0.000 title claims abstract description 23
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 25
239000002934 diuretic Substances 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
230000001882 diuretic effect Effects 0.000 claims abstract description 8
239000003937 drug carrier Substances 0.000 claims abstract description 5
206010020772 Hypertension Diseases 0.000 claims description 57
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
201000010099 disease Diseases 0.000 claims description 22
238000011282 treatment Methods 0.000 claims description 21
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 20
229960004699 valsartan Drugs 0.000 claims description 20
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 20
208000001647 Renal Insufficiency Diseases 0.000 claims description 19
208000020832 chronic kidney disease Diseases 0.000 claims description 19
208000022831 chronic renal failure syndrome Diseases 0.000 claims description 19
201000006370 kidney failure Diseases 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 18
208000037803 restenosis Diseases 0.000 claims description 18
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 17
238000000034 method Methods 0.000 claims description 15
206010048554 Endothelial dysfunction Diseases 0.000 claims description 13
230000008694 endothelial dysfunction Effects 0.000 claims description 13
208000010125 myocardial infarction Diseases 0.000 claims description 13
102000008186 Collagen Human genes 0.000 claims description 12
108010035532 Collagen Proteins 0.000 claims description 12
229920001436 collagen Polymers 0.000 claims description 12
201000001320 Atherosclerosis Diseases 0.000 claims description 11
206010016654 Fibrosis Diseases 0.000 claims description 11
230000004761 fibrosis Effects 0.000 claims description 11
230000002265 prevention Effects 0.000 claims description 11
206010007559 Cardiac failure congestive Diseases 0.000 claims description 10
206010019280 Heart failures Diseases 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 10
230000004083 survival effect Effects 0.000 claims description 10
208000008589 Obesity Diseases 0.000 claims description 9
238000002399 angioplasty Methods 0.000 claims description 9
230000001028 anti-proliverative effect Effects 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 9
208000029078 coronary artery disease Diseases 0.000 claims description 9
210000004351 coronary vessel Anatomy 0.000 claims description 9
230000001258 dyslipidemic effect Effects 0.000 claims description 9
208000003532 hypothyroidism Diseases 0.000 claims description 9
230000002989 hypothyroidism Effects 0.000 claims description 9
208000017169 kidney disease Diseases 0.000 claims description 9
235000020824 obesity Nutrition 0.000 claims description 9
238000007634 remodeling Methods 0.000 claims description 9
238000001356 surgical procedure Methods 0.000 claims description 9
208000011580 syndromic disease Diseases 0.000 claims description 9
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 8
208000032928 Dyslipidaemia Diseases 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
206010022489 Insulin Resistance Diseases 0.000 claims description 8
208000017170 Lipid metabolism disease Diseases 0.000 claims description 8
229950011548 fadrozole Drugs 0.000 claims description 8
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229960002003 hydrochlorothiazide Drugs 0.000 claims description 4
-1 supplementaltan Chemical compound 0.000 claims description 4
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
239000002081 C09CA05 - Tasosartan Substances 0.000 claims description 2
239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
229960002932 anastrozole Drugs 0.000 claims description 2
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
229960000932 candesartan Drugs 0.000 claims description 2
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
229960004563 eprosartan Drugs 0.000 claims description 2
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
229960000255 exemestane Drugs 0.000 claims description 2
229960002198 irbesartan Drugs 0.000 claims description 2
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
229960004773 losartan Drugs 0.000 claims description 2
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
229960000651 tasosartan Drugs 0.000 claims description 2
ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims description 2
229960005187 telmisartan Drugs 0.000 claims description 2
206010003210 Arteriosclerosis Diseases 0.000 claims 2
208000011775 arteriosclerosis disease Diseases 0.000 claims 2
208000035475 disorder Diseases 0.000 claims 1
230000008753 endothelial function Effects 0.000 claims 1
239000000203 mixture Substances 0.000 description 33
241000700159 Rattus Species 0.000 description 11
238000009472 formulation Methods 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
239000003826 tablet Substances 0.000 description 8
239000000126 substance Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
230000002861 ventricular Effects 0.000 description 7
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 6
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 6
206010011086 Coronary artery occlusion Diseases 0.000 description 6
206010061216 Infarction Diseases 0.000 description 6
229960002478 aldosterone Drugs 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000007941 film coated tablet Substances 0.000 description 6
239000008187 granular material Substances 0.000 description 6
230000007574 infarction Effects 0.000 description 6
210000004165 myocardium Anatomy 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
230000003637 steroidlike Effects 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102000012422 Collagen Type I Human genes 0.000 description 3
108010022452 Collagen Type I Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
229960000913 crospovidone Drugs 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000010191 image analysis Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
230000008569 process Effects 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
230000002485 urinary effect Effects 0.000 description 3
101800000733 Angiotensin-2 Proteins 0.000 description 2
102400000345 Angiotensin-2 Human genes 0.000 description 2
102000001187 Collagen Type III Human genes 0.000 description 2
108010069502 Collagen Type III Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
150000001325 aldosterones Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229950006323 angiotensin ii Drugs 0.000 description 2
239000003886 aromatase inhibitor Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
210000004413 cardiac myocyte Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229940096422 collagen type i Drugs 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
230000035487 diastolic blood pressure Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
238000012216 screening Methods 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000008873 Angiotensin II receptor Human genes 0.000 description 1
108050000824 Angiotensin II receptor Proteins 0.000 description 1
229940122815 Aromatase inhibitor Drugs 0.000 description 1
208000016998 Conn syndrome Diseases 0.000 description 1
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
230000000640 hydroxylating effect Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960003739 methyclothiazide Drugs 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
238000000465 moulding Methods 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940126347 non-steroidal aldosterone synthase inhibitor Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002315 pressor effect Effects 0.000 description 1
208000013846 primary aldosteronism Diseases 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
210000005241 right ventricle Anatomy 0.000 description 1
238000011336 routine blood sampling Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
210000000596 ventricular septum Anatomy 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000011706 wistar kyoto rat Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2001574092A 2000-04-12 2001-04-10 アルドステロンシンターゼインヒビター単体またはａｔ１−レセプターアンタゴニストとの組み合わせの新規医薬使用 Pending JP2003530343A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19674200P	2000-04-12	2000-04-12
US60/196,742		2000-04-12
PCT/EP2001/004116 WO2001076574A2 (en)	2000-04-12	2001-04-10	Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists

Publications (1)

Publication Number	Publication Date
JP2003530343A true JP2003530343A (ja)	2003-10-14

Family

ID=22726655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001574092A Pending JP2003530343A (ja)	2000-04-12	2001-04-10	アルドステロンシンターゼインヒビター単体またはａｔ１−レセプターアンタゴニストとの組み合わせの新規医薬使用

Country Status (19)

Country	Link
EP (1)	EP1282410A2 (es)
JP (1)	JP2003530343A (es)
KR (1)	KR20020089437A (es)
CN (1)	CN1422152A (es)
AR (1)	AR032316A1 (es)
AU (2)	AU7393801A (es)
BR (1)	BR0110079A (es)
CA (1)	CA2405895A1 (es)
HU (1)	HUP0301335A3 (es)
IL (1)	IL152081A0 (es)
MX (1)	MXPA02010091A (es)
NO (1)	NO20024920L (es)
NZ (1)	NZ521855A (es)
PE (1)	PE20020082A1 (es)
PL (1)	PL358459A1 (es)
RU (1)	RU2002129569A (es)
SK (1)	SK14612002A3 (es)
WO (1)	WO2001076574A2 (es)
ZA (1)	ZA200208204B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2021522289A (ja) *	2018-05-03	2021-08-30	ダミアンファーマアーゲー	アルドステロン症の治療における使用のためのｒ−ファドロゾール

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004518611A (ja) *	2000-07-27	2004-06-24	ファルマシア・コーポレーション	炎症関連障害を予防するか又は治療するためのアルドステロン遮断薬療法
US6777443B2 (en)	2001-05-15	2004-08-17	Novartis Ag	Dipeptide derivatives
US7232828B2 (en) *	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
CN100438911C (zh) *	2002-12-27	2008-12-03	武田药品工业株式会社	体重增加抑制剂
SE0300988D0 (sv) *	2003-04-03	2003-04-03	Astrazeneca Ab	New use
WO2005099695A1 (en) *	2004-04-19	2005-10-27	Novartis Ag	Drug delivery systems for the prevention and treatment of vascular diseases
ITTO20040760A1 (it) *	2004-11-03	2005-02-03	Uni Degli Studi Del Piemonte	Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare
EP1674080A1 (en) *	2004-12-24	2006-06-28	KRKA, D.D., Novo Mesto	Solid pharmaceutical composition comprising valsartan
ES2397552T3 (es) *	2004-12-24	2013-03-07	Krka	Composición farmacéutica sólida que comprende valsartán
US9271963B2 (en)	2005-03-03	2016-03-01	Universitat Des Saarlandes	Selective inhibitors of human corticosteroid synthases
TW200716636A (en) *	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
EP1842543A1 (en)	2006-04-05	2007-10-10	Speedel Pharma AG	Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808812A (en) *	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
TW200808813A (en)	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
EP2095819A1 (en)	2008-02-28	2009-09-02	Maastricht University	N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
UY32660A (es)	2009-05-28	2010-12-31	Novartis Ag	Derivados aminobutricos sustituidos como inhibidores de neprilisina
ME01923B (me)	2009-05-28	2015-05-20	Novartis Ag	Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
TWI627167B (zh)	2011-07-08	2018-06-21	諾華公司	用於高三酸甘油酯個體治療動脈粥狀硬化之方法
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
LT2956464T (lt)	2013-02-14	2018-07-10	Novartis Ag	Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
AP2016009019A0 (en)	2013-07-25	2016-02-29	Novartis Ag	Bioconjugates of synthetic apelin polypeptides
JP6501775B2 (ja)	2013-07-25	2019-04-17	ノバルティスアーゲー	心不全治療用の環状ポリペプチド
PE20171328A1 (es)	2015-01-23	2017-09-12	Novartis Ag	Conjugados de acidos grasos y apelina sintetica con mayor vida media
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
SG11201903803UA (en)	2016-10-27	2019-05-30	Damian Pharma Ag	Aldosterone synthase inhibitor
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP3887388A1 (en)	2018-11-27	2021-10-06	Novartis AG	Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
UY38485A (es)	2018-11-27	2020-06-30	Novartis Ag	Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en)	2018-11-27	2023-03-23	Novartis Ag	Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
TW202333563A (zh)	2021-11-12	2023-09-01	瑞士商諾華公司	用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2024241229A1 (en)	2023-05-24	2024-11-28	Novartis Ag	Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5252565A (en) *	1990-04-02	1993-10-12	Merrell Dow Pharmaceuticals Inc.	Haloethyl-substituted steroid enzyme inhibitors
JPH0971586A (ja) *	1995-09-07	1997-03-18	Yamanouchi Pharmaceut Co Ltd	新規な二環性縮合イミダゾール誘導体
ATE279916T1 (de) *	1996-07-22	2004-11-15	Renovo Ltd	Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
US5906987A (en) *	1997-03-10	1999-05-25	Schering Aktiengesellschaft And Board Of Regents	Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
FR2766821A1 (fr) *	1997-07-29	1999-02-05	Sanofi Sa	Derives de 1,3-oxazolinyl-biphenyle, leur procede de preparation et leur utilisation comme intermediaires de synthese
US5972921A (en) *	1997-12-12	1999-10-26	Hormos Medical Oy Ltd.	Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
ZA991922B (en) *	1998-03-11	1999-09-13	Smithkline Beecham Corp	Novel compositions of eprosartan.
PT2322174E (pt) *	1998-07-10	2015-10-27	Novartis Pharma Gmbh	Utilização combinada de valsartan e bloqueadores do canal de cálcio com objetivos terapêuticos

2001
- 2001-04-10 AR ARP010101698A patent/AR032316A1/es not_active Application Discontinuation
- 2001-04-10 NZ NZ521855A patent/NZ521855A/en unknown
- 2001-04-10 CN CN01807917A patent/CN1422152A/zh active Pending
- 2001-04-10 PL PL01358459A patent/PL358459A1/xx not_active Application Discontinuation
- 2001-04-10 KR KR1020027013486A patent/KR20020089437A/ko not_active Ceased
- 2001-04-10 RU RU2002129569/15A patent/RU2002129569A/ru not_active Application Discontinuation
- 2001-04-10 WO PCT/EP2001/004116 patent/WO2001076574A2/en not_active Ceased
- 2001-04-10 JP JP2001574092A patent/JP2003530343A/ja active Pending
- 2001-04-10 PE PE2001000328A patent/PE20020082A1/es not_active Application Discontinuation
- 2001-04-10 BR BR0110079-3A patent/BR0110079A/pt not_active IP Right Cessation
- 2001-04-10 AU AU7393801A patent/AU7393801A/xx active Pending
- 2001-04-10 IL IL15208101A patent/IL152081A0/xx unknown
- 2001-04-10 SK SK1461-2002A patent/SK14612002A3/sk unknown
- 2001-04-10 CA CA002405895A patent/CA2405895A1/en not_active Abandoned
- 2001-04-10 HU HU0301335A patent/HUP0301335A3/hu unknown
- 2001-04-10 AU AU2001273938A patent/AU2001273938B2/en not_active Ceased
- 2001-04-10 EP EP01940317A patent/EP1282410A2/en not_active Withdrawn
- 2001-04-10 MX MXPA02010091A patent/MXPA02010091A/es not_active Application Discontinuation
2002
- 2002-10-11 NO NO20024920A patent/NO20024920L/no not_active Application Discontinuation
- 2002-10-11 ZA ZA200208204A patent/ZA200208204B/en unknown

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2021522289A (ja) *	2018-05-03	2021-08-30	ダミアンファーマアーゲー	アルドステロン症の治療における使用のためのｒ−ファドロゾール
JP7470050B2 (ja)	2018-05-03	2024-04-17	ダミアンファーマアーゲー	アルドステロン症の治療における使用のためのｒ－ファドロゾール
JP2024102067A (ja) *	2018-05-03	2024-07-30	ダミアンファーマアーゲー	アルドステロン症の治療における使用のためのｒ－ファドロゾール

Also Published As

Publication number	Publication date
PE20020082A1 (es)	2002-02-21
EP1282410A2 (en)	2003-02-12
CN1422152A (zh)	2003-06-04
WO2001076574A2 (en)	2001-10-18
SK14612002A3 (sk)	2003-05-02
IL152081A0 (en)	2003-05-29
BR0110079A (pt)	2002-12-31
RU2002129569A (ru)	2004-03-27
WO2001076574A3 (en)	2002-04-25
ZA200208204B (en)	2003-10-14
NZ521855A (en)	2004-10-29
NO20024920D0 (no)	2002-10-11
HUP0301335A2 (hu)	2003-08-28
NO20024920L (no)	2002-11-27
PL358459A1 (en)	2004-08-09
AU7393801A (en)	2001-10-23
KR20020089437A (ko)	2002-11-29
AU2001273938B2 (en)	2005-03-03
MXPA02010091A (es)	2003-02-12
CA2405895A1 (en)	2001-10-18
AR032316A1 (es)	2003-11-05
HUP0301335A3 (en)	2006-02-28

Publication	Publication Date	Title
AU2001273938B2 (en)	2005-03-03	Novel medical use of aldosterone synthase inhibitors alone or in combination with ati-receptor antagonists
JP6603757B2 (ja)	2019-11-06	循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤
AU2001273938A1 (en)	2002-01-10	Novel medical use of aldosterone synthase inhibitors alone or in combination with ati-receptor antagonists
US20090036432A1 (en)	2009-02-05	Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic
US20030083342A1 (en)	2003-05-01	Combination of organic compounds
NZ534086A (en)	2006-08-31	Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a diuretic to treat various conditions
HK1059212B (en)	2006-12-08	Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
HK1053429A (en)	2003-10-24	Combination of organic compounds